Category of the product: Product from cannabis for medical use
Type of ATC Product: §KANOBIL® CANC FORTE is dispensed on prescription in duplicate upon recommendation of medical doctor, specialist in oncology or haematology.
triangle – absolute prohibition on driving a motor vehicle or handling machines.
§ – narcotic drug
Generics: tetrahydrocannabinol (THC), cannabidiol (CBD)
Oil solution for oral administration
(20 mg tetrahydrocannabinol (THC) and
20 mg cannabidiol (CBD))/ 1 ml
(2400 mg tetrahydrocannabinol (THC) and
2400 mg cannabidiol (CBD))120 ml

The text is not intended for self-medication!
Text is intended for informative purposes of healthcare workers.

tetrahydrocannabinol (THC), cannabidiol (CBD)


Stick strictly to the recommendations from your doctor. The therapy has to be recommended and monitored by a doctor, specialist in oncology or haematology.
Your doctor will tell you how many doses per day you should take and when. You must not change the doses or discontinue the treatment without consulting your doctor.

KANOBIL® CANC FORTE is for oral use.

Treatment with KANOBILCANC FORTE is not introducing treatment, but treatment for continuing with already started treatment in patients at whom, according to assessment of recommending physician, higher dosages are needed.

Shake the bottle before use. Use the plastic graduated syringe for pulling out a dose of the oil solution which is equal to the dose in accordance to the scheme given by your doctor.
Carefully press to release the content of the dosing syringe in the mouth and slowly swallow.

You can take KANOBIL® CANC FORTE with or without food. However, taking KANOBIL® CANC FORTE with food can affect the amount your body takes in. You should try, as far as possible, to take KANOBIL® CANC FORTE the same way in relation to food each time, so you get the same effect each time/

Daily dose of KANOBIL® CANC FORTE as continuing treatment to already started treatment is defined by physician who has recommended the treatment. Recommendation is made according to the assessment of patient condition; taking into consideration that one millilitre (1ml) of KANOBIL® CANC FORTE contains 10 mg tetrahydrocannabinol (THC) and 10 mg cannabidiol (CBD).
During the therapy course, at every 4, 8 and 12 weeks, a laboratory control has to be performed for haematological, hepatic and renal analyses in order to monitor the occurrence of side effects and tolerance to them. In case of variations that surpass the benefit/risk ratio and when there is no improvement of the clinical status, discontinuation of therapy should be considered.


KANOBIL® CANC FORTE should not be recommended for use in children and adolescents aged below 18, due to lack of safety and efficacy information.



(20 mg tetrahydrocannabinol (THC) and 20 mg cannabidiol (CBD))/ 1 ml
(2400 mg tetrahydrocannabinol (THC) and 2400 mg cannabidiol (CBD))120 ml


KANOBIL® CANC FORTE can be administered in adult patients as symptomatic adjuvant therapy to regular therapy in cases of:
Malignant diseases - for improvement of the symptoms of:
-Chemotherapy-induced nausea and vomiting in patients in whom the standard therapy with other anti-nausea medicinal products (such as 5-HT3 agonists) does not produce the expected results.


Do not take KANOBIL® CANC FORTE if:
-if you are hypersensitive to cannabinoids or to any of the excipients;
-if you or anyone from your family has any issues related to the mental health, like schizophrenia, psychoses or other sever psychiatric conditions; this does not include the depression which results from your primary condition;
-if you are pregnant or breastfeeding.
Do not take KANOBIL® CANC FORTE if any of the above applies to you. If you are not sure, talk to your doctor or pharmacist before taking KANOBIL® CANC FORTE.


A box with a glass bottle containing 120 ml of the oil solution (equal to 120 doses) and a plastic graduated dosing syringe.Prescription in two copies with the mark “copy” on the second copy and with the ordinal number from the evidence book of prescribed medicines containing narcotics and psychotropic substances.